Literature DB >> 12691626

Low neuropsychologic performance among adult cancer survivors treated with chemotherapy.

Robert J Ferguson1, Tim A Ahles.   

Abstract

Decline in neuropsychologic test performance following adjuvant chemotherapy for various types of cancer has gained much research attention over the past decade. From available data, about one fourth to one third of individuals undergoing systemic chemotherapy exhibit measurable decrements in performance of standard tests of cognitive function. Many cancer survivors report that cognitive problems interfere with function and compromise quality of life. However, these declines appear subtle and there are little available longitudinal data examining pre- to post-treatment cognitive change. Further, there is little available evidence identifying the causes of cognitive decline. This paper reviews current literature on low neuropsychologic performance following systemic chemotherapy and hypotheses on the causes of cognitive symptoms following chemotherapy. Future research directions, with emphasis on longitudinal research design as well as treatment implications, are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12691626     DOI: 10.1007/s11910-003-0081-2

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  29 in total

1.  Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

Authors:  Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

Review 2.  Quality of life among long-term cancer survivors.

Authors:  B R Ferrell; K Hassey Dow
Journal:  Oncology (Williston Park)       Date:  1997-04       Impact factor: 2.990

3.  Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center.

Authors:  B E Tardiff; M F Newman; A M Saunders; W J Strittmatter; J A Blumenthal; W D White; N D Croughwell; R D Davis; A D Roses; J G Reves
Journal:  Ann Thorac Surg       Date:  1997-09       Impact factor: 4.330

4.  Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients.

Authors:  P M Silberfarb; D Philibert; P M Levine
Journal:  Am J Psychiatry       Date:  1980-05       Impact factor: 18.112

5.  The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons.

Authors:  M N Haan; L Shemanski; W J Jagust; T A Manolio; L Kuller
Journal:  JAMA       Date:  1999-07-07       Impact factor: 56.272

Review 6.  Update on adjuvant chemotherapy for early breast cancer.

Authors:  N J McCarthy; S M Swain
Journal:  Oncology (Williston Park)       Date:  2000-09       Impact factor: 2.990

7.  Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation.

Authors:  R Komaki; C A Meyers; D M Shin; A S Garden; K Byrne; J A Nickens; J D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-08-30       Impact factor: 7.038

Review 8.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

Authors:  Eric P Winer; Clifford Hudis; Harold J Burstein; Rowan T Chlebowski; James N Ingle; Stephen B Edge; Eleftherios P Mamounas; Julie Gralow; Lori J Goldstein; Kathleen I Pritchard; Susan Braun; Melody A Cobleigh; Amy S Langer; Judy Perotti; Trevor J Powles; Timothy J Whelan; George P Browman
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

Review 9.  Cognitive assessment for postmenopausal women and general assessment of their mental health.

Authors:  B B Sherwin
Journal:  Psychopharmacol Bull       Date:  1998

10.  Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection.

Authors:  R A Stern; S G Silva; N Chaisson; D L Evans
Journal:  Arch Neurol       Date:  1996-02
View more
  21 in total

1.  Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial.

Authors:  Robert J Ferguson; Brenna C McDonald; Michael A Rocque; Charlotte T Furstenberg; Susan Horrigan; Tim A Ahles; Andrew J Saykin
Journal:  Psychooncology       Date:  2010-12-02       Impact factor: 3.894

Review 2.  Candidate mechanisms for chemotherapy-induced cognitive changes.

Authors:  Tim A Ahles; Andrew J Saykin
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

Review 3.  Memory and cancer: a review of the literature.

Authors:  Graham J McDougall; JoAnn S Oliver; Forrest Scogin
Journal:  Arch Psychiatr Nurs       Date:  2014-03-22       Impact factor: 2.218

4.  Spatial Memory Performance Associated with Measures of Immune Function in Elderly Female Rhesus Macaques.

Authors:  Gwendolen E Haley; Henryk F Urbanski; Steven G Kohama; Ilhem Messaoudi; Jacob Raber
Journal:  Eur Geriatr Med       Date:  2011-04-01       Impact factor: 1.710

5.  Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy.

Authors:  Robert J Ferguson; Brenna C McDonald; Andrew J Saykin; Tim A Ahles
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

6.  The antimetabolite ara-CTP blocks long-term memory of conditioned taste aversion.

Authors:  Jianpeng Wang; Keqin Ren; Javier Pérez; Alcino J Silva; Sandra Peña de Ortiz
Journal:  Learn Mem       Date:  2003 Nov-Dec       Impact factor: 2.460

Review 7.  Cancer survivorship care: exploring the role of the general internist.

Authors:  Susan Hong; Larissa Nekhlyudov; Aarati Didwania; Olufunmilayo Olopade; Pamela Ganschow
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

Review 8.  Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer.

Authors:  Andrew H Miller; Sonia Ancoli-Israel; Julienne E Bower; Lucile Capuron; Michael R Irwin
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

9.  The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9.

Authors:  Debra L Barton; Kelli Burger; Paul J Novotny; Tom R Fitch; Sadhna Kohli; Gamini Soori; Mary Beth Wilwerding; Jeff A Sloan; Lisa A Kottschade; Kendrith M Rowland; Shaker R Dakhil; Daniel A Nikcevich; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2012-11-13       Impact factor: 3.603

Review 10.  Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments.

Authors:  Thomas W McAllister; Tim A Ahles; Andrew J Saykin; Robert J Ferguson; Brenna C McDonald; Lionel D Lewis; Laura A Flashman; C Harker Rhodes
Journal:  Curr Psychiatry Rep       Date:  2004-10       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.